Prisys Biotech ("PRISYS"), located in Shanghai, China, is a leading contract research organization (CRO) focuses on services for new drug preclinical development. With her specialized non-human primate ('NHP') technology platforms, industrial-scale facilities, and dedicated & experienced team of talents, PRISYS aim to be the lead innovator and solution provider on preclinical translation, by delivering high-quality research services with exquisite designs to Biopharma researchers across the globe. PRISYS' end-to-end solutions covers various stages of drug development: from non-clinical proof-of-concept to assistant decision for clinical trial entering ; from standard preclinical PK/PD/Tox to customized NHP Model-based drug efficacy.
Vision: Translational Advancement for Human Health
We aspire to be the leading innovator in non-human primate disease modeling and the capstone platform with global innovation-centered collaborations, delivering more translational science and transformational technologies for new medicine.
Mission: Solidifying Innovations of New Medicine
- We look to define the new milestone advancement of pharmaceutical interventions for human disease.
- We innovate the NHP translational medicine platform providing unsurpassed values and quality of science to the biomedical industry.
- We are pioneers and problem solvers to accelerate the development of new therapeutics.
Full Accreditation From AAALAC
PRISYS is proud to announce that we have achieved full accreditation from AAALAC International, a globally recognized standard for excellence in animal care and use in research. This prestigious accreditation underscores our unwavering commitment to maintaining the highest standards of ethical and humane treatment of research animals.
